Shandong Weigao Blood Purification Products Co (SHSE:603014) Beneish M-Score: -2.62 (As of Jun. 30, 2026)


SHSE:603014 Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
38 GF Score
Price ¥36.00
! 2 Warning Signs
View Full Analysis

What is Shandong Weigao Blood Purification Products Co Beneish M-Score?

Shandong Weigao Blood Purification Products Co SHSE:603014 +9.99% 38 Beneish M-Score is -2.62 as of Jun. 30, 2026. GuruFocus rates SHSE:603014 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Shandong Weigao Blood Purification Products Co ranks better than 54.38% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.62 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shandong Weigao Blood Purification Products Co's Beneish M-Score or its related term are showing as below:

SHSE:603014' s Beneish M-Score Range Over the Past 10 Years
Min: -2.65   Med: -2.62   Max: -1.94
Current: -2.62

During the past 6 years, the highest Beneish M-Score of Shandong Weigao Blood Purification Products Co was -1.94. The lowest was -2.65. And the median was -2.62.


Shandong Weigao Blood Purification Products Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Shandong Weigao Blood Purification Products Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Weigao Blood Purification Products Co Beneish M-Score Chart

Shandong Weigao Blood Purification Products Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -2.65

Shandong Weigao Blood Purification Products Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.94 0.00 -2.65 -2.62

SHSE:603014 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Shandong Weigao Blood Purification Products Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Weigao Blood Purification Products Co Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Blood Purification Products Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shandong Weigao Blood Purification Products Co's Beneish M-Score falls into.


SHSE:603014
38GF Score
Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Weigao Blood Purification Products Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shandong Weigao Blood Purification Products Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9087+0.528 * 1.0479+0.404 * 0.8401+0.892 * 1.0325+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9209+4.679 * -0.024688-0.327 * 0.8159
=-2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥946 Mil.
Revenue was 904.266 + 1032.667 + 971.372 + 868.689 = ¥3,777 Mil.
Gross Profit was 351.939 + 402.621 + 388.137 + 358.649 = ¥1,501 Mil.
Total Current Assets was ¥4,667 Mil.
Total Assets was ¥8,596 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,281 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥377 Mil.
Total Current Liabilities was ¥1,259 Mil.
Long-Term Debt & Capital Lease Obligation was ¥11 Mil.
Net Income was 118.304 + 141.519 + 120.541 + 107.88 = ¥488 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 1.648 + 308.374 + 296.489 + 93.942 = ¥700 Mil.
Total Receivables was ¥1,008 Mil.
Revenue was 895.992 + 959.255 + 1018.703 + 784.279 = ¥3,658 Mil.
Gross Profit was 366.646 + 402.172 + 421.444 + 333.522 = ¥1,524 Mil.
Total Current Assets was ¥3,060 Mil.
Total Assets was ¥7,067 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,374 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥397 Mil.
Total Current Liabilities was ¥1,278 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(945.592 / 3776.994) / (1007.867 / 3658.229)
=0.250356 / 0.275507
=0.9087

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1523.784 / 3658.229) / (1501.346 / 3776.994)
=0.416536 / 0.397498
=1.0479

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4667.307 + 3281.016) / 8595.761) / (1 - (3059.655 + 3373.521) / 7066.76)
=0.075321 / 0.089657
=0.8401

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3776.994 / 3658.229
=1.0325

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 3373.521)) / (0 / (0 + 3281.016))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(377.456 / 3776.994) / (396.978 / 3658.229)
=0.099936 / 0.108516
=0.9209

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((10.871 + 1259.143) / 8595.761) / ((1.87 + 1277.867) / 7066.76)
=0.147749 / 0.181092
=0.8159

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(488.244 - 0 - 700.453) / 8595.761
=-0.024688

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shandong Weigao Blood Purification Products Co has a M-score of -2.62 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.62 mean?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Beneish M-Score of -2.62 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #349 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 45.6%.
Is Shandong Weigao Blood Purification Products Co's Beneish M-Score too high?
Shandong Weigao Blood Purification Products Co's current Beneish M-Score is -2.62. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #349 out of 765 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #349 out of 765 companies for Beneish M-Score. This puts Shandong Weigao Blood Purification Products Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. Shandong Weigao Blood Purification Products Co's current Beneish M-Score is -2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Beneish M-Score of -2.62. The current Beneish M-Score is -2.62. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Beneish M-Score is -2.62 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shandong Weigao Blood Purification Products Co Business Description

Address No. 7, Weigao West Road, Torch High-tech Industrial Development Zone, Shandong Province, Weihai, CHN, 264200
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
38GF Score

Get the complete analysis for SHSE:603014

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.00
Price